Φορτώνει......
A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles of paclitaxel 175 mg / m2 and carboplatin AUC5 were a...
Αποθηκεύτηκε σε:
Κύριοι συγγραφείς: | , , , , , , , |
---|---|
Μορφή: | Artigo |
Γλώσσα: | Russo |
Έκδοση: |
Remedium Group LLC
2019-06-01
|
Σειρά: | Медицинский совет |
Θέματα: | |
Διαθέσιμο Online: | https://www.med-sovet.pro/jour/article/view/3060 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|